Madrigal's $600M offering; PureTech to return $100M to shareholders

19 Mar 2024
endpts.com
Drug Approval
Madrigal Pharmaceuticals’s $600M offering: The company is raising money to boost the launch of its landmark NASH drug Rezdiffra. It priced 750,000 shares at $260 apiece, with a goal to bring in $600 million. That’s $100 million more than the company initially penciled in when it announced the proposed offering on Monday. Rezdiffra, also known as resmetirom, is the first approved drug for NASH, a liver disease now often referred to as metabolic dysfunction-associated steatohepatitis. — Nicole DeFeudis
Madrigal's $600M offering; PureTech to return $100M to shareholders
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.